Cargando…
Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors
BACKGROUND: Hidradenitis suppurativa (HS) is an independent risk factor for the development of subclinical atherosclerosis. Tumour necrosis factor (TNF) inhibitors are effective for the treatment of recalcitrant moderate‐to‐severe HS. However, the effect of treatment with TNF inhibitors on subclinic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155849/ https://www.ncbi.nlm.nih.gov/pubmed/36973990 http://dx.doi.org/10.1111/srt.13302 |
_version_ | 1785036414791974912 |
---|---|
author | Oba, Muazzez Cigdem Askin, Ozge Gunver, Mehmet Guven Kocaarslan, Gokce Alis, Deniz Can Engin, Burhan |
author_facet | Oba, Muazzez Cigdem Askin, Ozge Gunver, Mehmet Guven Kocaarslan, Gokce Alis, Deniz Can Engin, Burhan |
author_sort | Oba, Muazzez Cigdem |
collection | PubMed |
description | BACKGROUND: Hidradenitis suppurativa (HS) is an independent risk factor for the development of subclinical atherosclerosis. Tumour necrosis factor (TNF) inhibitors are effective for the treatment of recalcitrant moderate‐to‐severe HS. However, the effect of treatment with TNF inhibitors on subclinical atherosclerosis in HS patients has not been previously investigated. OBJECTIVES: In this study, we aimed to assess changes in biochemical parameters (fasting blood glucose and lipid levels) and carotid intima‐media thickness (CIMT) values in Hurley stage II and III HS patients undergoing treatment with TNF inhibitors. METHODS: This was a single center prospective study including 30 patients with Hurley stage II and III HS and 30 healthy controls (HCs). Baseline values of biochemical parameters and CIMT were compared to the values recorded after at least 6 months of TNF inhibitor therapy. RESULTS: CIMT values of the HS patients significantly exceeded those of HCs (for right p = 0.011 and for left p = 0.017). After at least 6 months of TNF inhibitor therapy, there was a statistically significant decrease in fasting blood glucose (p = 0.001), whereas total cholesterol levels significantly increased (p = 0.001). CIMT values also significantly increased (for right p = 0.02 and for left p = 0.01). STUDY LIMITATIONS AND CONCLUSIONS: Small sample size is limitation of the current study. Our study shows that patients with Hurley stage II and III HS undergoing TNF inhibitor therapy are under risk for progression of subclinical atherosclerosis. |
format | Online Article Text |
id | pubmed-10155849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101558492023-08-11 Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors Oba, Muazzez Cigdem Askin, Ozge Gunver, Mehmet Guven Kocaarslan, Gokce Alis, Deniz Can Engin, Burhan Skin Res Technol Original Articles BACKGROUND: Hidradenitis suppurativa (HS) is an independent risk factor for the development of subclinical atherosclerosis. Tumour necrosis factor (TNF) inhibitors are effective for the treatment of recalcitrant moderate‐to‐severe HS. However, the effect of treatment with TNF inhibitors on subclinical atherosclerosis in HS patients has not been previously investigated. OBJECTIVES: In this study, we aimed to assess changes in biochemical parameters (fasting blood glucose and lipid levels) and carotid intima‐media thickness (CIMT) values in Hurley stage II and III HS patients undergoing treatment with TNF inhibitors. METHODS: This was a single center prospective study including 30 patients with Hurley stage II and III HS and 30 healthy controls (HCs). Baseline values of biochemical parameters and CIMT were compared to the values recorded after at least 6 months of TNF inhibitor therapy. RESULTS: CIMT values of the HS patients significantly exceeded those of HCs (for right p = 0.011 and for left p = 0.017). After at least 6 months of TNF inhibitor therapy, there was a statistically significant decrease in fasting blood glucose (p = 0.001), whereas total cholesterol levels significantly increased (p = 0.001). CIMT values also significantly increased (for right p = 0.02 and for left p = 0.01). STUDY LIMITATIONS AND CONCLUSIONS: Small sample size is limitation of the current study. Our study shows that patients with Hurley stage II and III HS undergoing TNF inhibitor therapy are under risk for progression of subclinical atherosclerosis. John Wiley and Sons Inc. 2023-03-05 /pmc/articles/PMC10155849/ /pubmed/36973990 http://dx.doi.org/10.1111/srt.13302 Text en © 2023 The Authors. Skin Research and Technology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Oba, Muazzez Cigdem Askin, Ozge Gunver, Mehmet Guven Kocaarslan, Gokce Alis, Deniz Can Engin, Burhan Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors |
title | Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors |
title_full | Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors |
title_fullStr | Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors |
title_full_unstemmed | Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors |
title_short | Subclinical atherosclerosis in patients with hidradenitis suppurativa treated with TNF inhibitors |
title_sort | subclinical atherosclerosis in patients with hidradenitis suppurativa treated with tnf inhibitors |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155849/ https://www.ncbi.nlm.nih.gov/pubmed/36973990 http://dx.doi.org/10.1111/srt.13302 |
work_keys_str_mv | AT obamuazzezcigdem subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors AT askinozge subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors AT gunvermehmetguven subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors AT kocaarslangokce subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors AT alisdenizcan subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors AT enginburhan subclinicalatherosclerosisinpatientswithhidradenitissuppurativatreatedwithtnfinhibitors |